Pharmaceutical care on the elderly patients of pemetrexed combined with carboplatin with non-small cell lung cancer
YANG Jun, CHEN Zhe, HE Fei, ZHU Zhi-xiang, ZHOU Hai-yan, LI Guo-hui*
Department of Pharmacy, National Cancer centre/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021, China
Abstract：Objective: To probe into the operation and management of pharmaceutical care on the elderly patients with non-small cell lung cancer. Methods: By adjusting the chemotherapy drug dosage and analgesia drug, combined with the clinical guidelines, clinical pharmacist can summarize the main points of pharmaceutical care of elderly patient with NSCLC. Results: The elderly patients of have better clinical tolerance with carboplatin, and should be monitored the renal function because of the nephrotoxicity of platinum and renal excretion of pemetrexed; pharmacist can adjust the dose of chemotherapy combination drugs (anticoagulant, lipid-lowering drug, analgesia) in order to improve patients’ compliance with chemotherapy, and reduce the adverse drug reaction. Conclusion: With the pharmacists’ participating in clinical chemotherapy of elderly NSCLC patients, it was to formulate individualized dosage regimen, and improve the patient's medication compliance and quality of life.
杨珺，陈喆，贺飞，朱志祥，周海燕，李国辉. 1 例培美曲塞联合卡铂治疗老年非小细胞肺癌患者的药学监护[J]. 临床药物治疗杂志, 2017, 15(3): 52-55.
YANG Jun, CHEN Zhe, HE Fei, ZHU Zhi-xiang, ZHOU Hai-yan, LI Guo-hui. Pharmaceutical care on the elderly patients of pemetrexed combined with carboplatin with non-small cell lung cancer. CLINICAL MEDICATION JOURNAL, 2017, 15(3): 52-55.
[1] Wang Z．Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies[J]. Int J Clin Exp Med,2014, 7(11):3833-3842．
[2] 徐凌, 赵昕, 史清明．70 岁以上老年肺癌的临床流行病学分析[J].安徽预防医学杂志, 2012, 18(1):43-44．
[3] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology:Non-small Cell Lung Cancer(Version 5.2017)[EB/OL].(2017-03-16)[2017-10-10]. https://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Acceessed 16 Mar.2017.In.
[4] Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and nonelderly patients: why is toxicity increased in elderly patients?[J]. J Clin Oncol, 2004, 22(14):2901-2908.
[5] Langer C J, Manola.J, Bernado P, et al.Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer:implications of Eastern Cooperative Oncology Group 5592, a randomized trial[J].J Natl Cancer Inst, 2002, 94(3):173-181.
[6] Bargieri JV, Quadros AA, Pereira RD,et al.Basal metabolic rate and body composition in patients with post-polio syndrome[J].Ann Nutr Metab, 2008, 53(3):199-204.
[7] Gimble J M, Sutton G M, Ptitsyn A A, et al. Circadian rhythms in adipose tissue: an update[J].Curr Opin Clin Nutr Metab Care, 2011,14(6): 554-561.
[8] Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy[J]. Clin Pharmacokinet, 2000, 39(3): 215-231.
[9] Griggs J J, Mangu P B, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with Cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2012,30(13): 1553-1561.
[10] Thompson L A, Lawson A P, Sutphin S D, et al. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients[J]. J Oncol Pract, 2010, 6(3):141-145.
[11] Newell D R. Clinical pharmacokinetics of antitumor antifolates[J]. Semin Oncol, 1999, 26(3):74.
[12] Maria M, James A, Karen B, et al. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling[J].Drug Metab Dispose, 2015,43(3):325-334.
[13] Morrissey K M, Stocker S L, Wittwer M B, et al. Renal transporters in drug development[J].Annu Rev Pharmacol Toxicol, 2013, 53(1):503-529．
[14] 孙晨, 奇锦峰, 张娜, 等. 膜转运体在肾清除药物过程中的作用研究进展[J]. 中国药理学与毒理学杂志, 2014, 28(4):625-631.
[15] Sweeney C J, Takimoto C H, Latz J E, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer[J].Clin Cancer Res, 2006, 12(2):536-542.
2017, Vol. 15 
